Back to previous page

What Did We Learn From COVID-19 Vaccine Development?


1 min read

Written by


Argos Multilingual

Published on

30 Jul 2021

Before the COVID-19 pandemic, no vaccine had ever been developed in under four years – so hoping for one by the summer of 2021 seemed absurdly optimistic. But at the start of December 2020, a vaccine made by Pfizer with German biotech firm BioNTech became the first fully-tested immunization to be approved for emergency use.

The world was able to develop COVID-19 vaccines so quickly because of years of previous research on related viruses, faster methods of manufacturing vaccines, enormous sums of funding that allowed firms to run multiple trials in parallel, and regulators cutting red tape wherever possible.

The experiences of the past year have challenged our whole paradigm of what is possible in vaccine development. New ways of making vaccines have been validated by the COVID-19 response, which has also shown that the development process can be accelerated substantially without compromising on safety.

All this has exciting implications for the future, especially since the factors mentioned above can and likely will translate to other vaccine efforts. To learn more, download our article, “COVID-19 Rapid Vaccine Development – Leveraging the Lessons Learned.”

Share this post

Copy LinkFacebookXLinkedIn

Get in touch

Ready to get started?

We are committed to giving you freedom of choice while providing subject matter expertise and customized strategies to fit your business needs.

Contact us

Join our newsletter

Stay in the know with all things translation with our ad-free newsletter. Every other week, no spam. We guarantee.